NTLA Q2 2020 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+46.3% YoY

Gross Profit

-$22M-132.3% margin

Operating Income

-$33M-203.1% margin

Net Income

-$32M-199.2% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

+25.9%

Cash Flow

Operating Cash Flow

$57M

Free Cash Flow

$56M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$491M

Total Liabilities

$139M

Stockholders' Equity

$352M

Cash & Equivalents

$362M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$11M	+46.3%
Gross Profit	-$22M	-$14M	-50.0%
Operating Income	-$33M	-$27M	-20.3%
Net Income	-$32M	-$26M	-26.1%